Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.52 |
| ▸ | MTR | Q99707 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 11/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 11/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1976916 | 0.88 | PARP1 (0.56) | PARP1MTRSCN1ASCN5ASCN9A | |
| Trifluoroacetic Acid SCHEMBL4782071 | 0.81 | CALCRL (0.48) | PARP1 | |
| Trifluoroacetic Acid SCHEMBL3089861 | 0.81 | HTR2A (0.50) | PARP1SCN1ASCN5ASCN9AHTR2C | |
| SCHEMBL18216849 | 0.78 | MTR (0.59) | MTRSCN1ASCN5ASCN9ACRBN | |
| SCHEMBL29961279 | 0.78 | MTR (0.59) | MTRSCN1ASCN5ASCN9ACRBN | |
| Trifluoroacetic Acid SCHEMBL4781145 | 0.75 | CALCRL (0.46) | HTR2CHTR2B | |
| SCHEMBL2183088 | 0.75 | MTR (0.60) | PARP1MTRSCN1ASCN5ASCN9A | |
| SCHEMBL31252793 | 0.75 | MTR (0.60) | PARP1MTRSCN1ASCN5ASCN9A | |
| SCHEMBL27791700 | 0.74 | PARP1 (0.45) | PARP1MTRSCN1ASCN5ASCN9A | |
| SCHEMBL30015409 | 0.74 | HTR2C (0.61) | PARP1CRBNHTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799806-B2 | Substituted n-benzyl piperidines as somatostatin receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2142528-B1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | HOFFMANN LA ROCHE (CH) | 2010-07-07 | — | — | EP | disclosed |
| EP-2142528-A1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008122510-A1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249101-A1 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249101-A1 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES | SSTR5, SSTR3, SSTR1 | PARP1 3169/4885MTR 3378/4885SCN1A 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.